Trial Profile
A Phase 2 Clinical Trial of Galidesivir for Yellow Fever
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2020
Price :
$35
*
At a glance
- Drugs Galidesivir (Primary)
- Indications Yellow fever
- Focus Therapeutic Use
- 13 Mar 2020 New trial record
- 05 Mar 2020 According to a BioCryst Pharmaceuticals media release, Galidesivir is being developed in this Phase 2 clinical trial (Yellow Fever) under contracts with the National Institute of Allergy and Infectious Diseases (NIAID) and U.S. Department of Health and Human Services (HHS).